CTLA4 and melanoma: This randomized controlled, open-label, international phase III study randomized 272 patients with unresectable stage IIIC or IV melanoma progressing after anti-CTLA-4 treatment or after anti-CTLA-4 treatment and a BRAF inhibitor for BRAFV600-mutated tumors to IV nivolumab 3 mg/kg every 2 weeks and 133 to ICC (Table 2).